These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

719 related articles for article (PubMed ID: 21617603)

  • 1. Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
    Welzel D; Hull R; Fareed J
    Int Angiol; 2011 Jun; 30(3):199-211. PubMed ID: 21617603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Huisman MV; Quinlan DJ; Dahl OE; Schulman S
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Nieto JA; Espada NG; Merino RG; González TC
    Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
    Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
    Loke YK; Kwok CS
    J Clin Pharm Ther; 2011 Feb; 36(1):111-24. PubMed ID: 21198726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
    Lereun C; Wells P; Diamantopoulos A; Rasul F; Lees M; Sengupta N
    J Med Econ; 2011; 14(2):238-44. PubMed ID: 21385145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
    Quinlan DJ; Eriksson BI
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):171-82. PubMed ID: 23953905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term benefits of preventing venous thromboembolic events.
    Cohen AT
    Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.
    Augoustides JG
    J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):1208-12. PubMed ID: 21982327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New anticoagulants: dabigatran, rivaroxaban and apixaban].
    Vargas Ruiz AG; Ramírez López AN; Medina Viramontes ME
    Gac Med Mex; 2012; 148(3):257-64. PubMed ID: 22820359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
    Friedman RJ
    Orthopedics; 2011 Oct; 34(10):795-804. PubMed ID: 21956181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.
    Pfeilschifter W; Luger S; Brunkhorst R; Lindhoff-Last E; Foerch C
    Cerebrovasc Dis; 2013; 36(2):115-9. PubMed ID: 24029592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing postsurgical venous thromboembolism: pharmacological approaches.
    Tufano A; Coppola A; Cerbone AM; Ruosi C; Franchini M
    Semin Thromb Hemost; 2011 Apr; 37(3):252-66. PubMed ID: 21455859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New oral anticoagulant agents: the quandary of anticoagulation in the elderly].
    Páramo JA
    Med Clin (Barc); 2013 Oct; 141(8):346-8. PubMed ID: 23831406
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 36.